254
Views
12
CrossRef citations to date
0
Altmetric
Article

The Ferula Assa-foetida Essential Oil Nanoemulsion (FAEO-NE) as the Selective, Apoptotic, and Anti-Angiogenic Anticancer Compound in Human MCF-7 Breast Cancer Cells and Murine Mammary Tumor Models

, , , &
Pages 2196-2206 | Received 25 Mar 2021, Accepted 21 Sep 2021, Published online: 05 Oct 2021
 

Abstract

The Ferula assa-foetida (FA) is the healthy common-consumed anticancer beverage in Iranian folk medicine. In the current study, we aimed to produce a nanoemulsion-based drug delivery system containing FA essential oil (FAEO) and evaluate its antioxidant and anticancer activity on both MCF-7 cells and murine mammary cancer tissue. The FAEO-loaded nanoemulsion (FAEO-NE) was produced and characterized by DLS, TEM, FTIR, and Zeta potential analysis. Radical (ABTS and DPPH) scavenging activity, cytotoxic, apoptotic, and anti-angiogenic potentials of the FAEO-NE were studied by applying antioxidant (ABTS-DPPH), MTT, AO/PI cell staining, and Q-PCR analysis. Finally, its anti-tumor impact was evaluated on murine mammary tumor models. The FAEO-NE exhibited a meaningful antioxidant activity. Also, its significant cell-selective cytotoxic, apoptotic, and anti-angiogenic impacts on MCF-7 cancer cells indicated its anticancer potential. Moreover, the progressive destruction of the murine mammary glands cancer tissue confirmed their anticancer activity. Regarding the FAEO-NE cell-selective cytotoxic, apoptotic, and anti-angiogenic activity on MCF-7 breast cancer cells, it has the potential to be studied as a safe efficient anti-breast cancer agent.

Acknowledgment

This work was supported by, Islamic Azad University, Mashhad, Iran and therefore is appreciated by the author.

Disclosure Statement

No potential conflict of interest was reported by the authors.

Funding

This research was performed at personal expense in the laboratory of Islamic Azad University of Mashhad.

Funding

The author(s) reported there is no funding associated with the work featured in this article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.